OncoMatch/Clinical Trials/NCT05865743
Perioperative SDD to Prevent Infectious Complications After Esophagectomy
Is NCT05865743 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies SDD for esophageal cancer.
Treatment: SDD — The primary aim of the PERSuaDER-trial is to evaluate the effect of SDD on infectious complications after esophagectomy, focussed on the prevention of pneumonia
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Esophageal Carcinoma
Disease stage
Required: Stage CT1B-4A, N0-3
cT1b-4a,N0-3,M0
Prior therapy
Cannot have received: upper gi surgery
Lab requirements
Kidney function
No chronic renal failure (GFR < 15 mls/min) or chronic intermittent hemo- or peritoneal dialysis
Patients with documented chronic renal failure (GFR < 15 mls/min) or who are on chronic intermittent hemo- or peritoneal dialysis [excluded]
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05865743 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior upper gi surgery disqualifies patients from enrollment.
What disease stage is eligible?
Stage CT1B-4A or N0-3 is required.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages